Related Experiment Video

Updated: Aug 18, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

Hypercholesterolemia inhibits L-type calcium current in coronary macro-, not microcirculation

D K Bowles1, C L Heaps, J R Turk

  • 1Department of Biomedical Sciences, University of Missouri, Columbia, MO 65211, USA. bowlesd@missouri.edu

Insights

High cholesterol (HC) reduces calcium channel activity in large coronary arteries, impacting coronary heart disease risk. This effect in coronary arterial smooth muscle cells was reversed by cholesterol reduction.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Atherosclerosis Research

Background:

  • Hypercholesterolemia (HC) is a significant risk factor for coronary heart disease (CHD).
  • Coronary ion regulation, particularly calcium, is implicated in CHD development.
  • The impact of high-fat, high-cholesterol diets on coronary arterial smooth muscle (CASM) ion channels remains unclear.

Purpose of the Study:

  • To investigate the effect of diet-induced HC on CASM voltage-gated calcium current (I(Ca)).
  • To determine if HC affects calcium channel activity in different sizes of coronary arteries.

Main Methods:

  • Miniature swine were fed a high-fat, high-cholesterol diet for 20-24 weeks to induce HC.
  • CASM were isolated from various coronary artery segments (right coronary artery, small arteries, arterioles).
  • Whole-cell voltage clamp electrophysiology was used to measure I(Ca).

Main Results:

  • Diet-induced HC significantly reduced L-type I(Ca) by approximately 30% in large coronary arteries (right coronary artery).
  • I(Ca) in the coronary microcirculation (small arteries and arterioles) was not affected by HC.
  • Neither voltage-dependent activation nor Ca(v)1.2 mRNA/protein levels were altered by HC.
  • Inhibition of I(Ca) was reversible with a cholesterol scavenger and mimicked by cholesterol addition.

Conclusions:

  • CASM L-type I(Ca) is decreased in large coronary arteries during early atherosclerosis due to diet-induced HC.
  • The coronary microcirculation's calcium channel activity remains unaffected.
  • Increased membrane free cholesterol in CASM likely causes the observed inhibition of calcium channel activity in larger arteries.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...